Reduced fluence rate PDT

Abstract

The invention relates to the use of reduced fluence rate PDT to treat neovasculature, particularly choroidal neovasculature (CNV). Reduced fluence rate PDT decreases the likelihood of molecular oxygen being the limiting factor in the photodynamic reaction so that the concentration of either photons (light intensity) or photosensitizer in the target tissue controls the photodynamic reaction.

1 . A method for treating choroidal neovasculature using photodynamic therapy (PDT), comprising administering a photosensitizer (PS) to a subject afflicted with said neovasculature, and irradiating the PS with electromagnetic radiation containing a wavelength absorbed by said PS at a reduced fluence rate which does not deplete molecular oxygen levels in said neovasculature.  
     
     
         2 . A method of treating choroidal neovasculature, comprising irradiating a subject afflicted with said neovasculature, and to whom a photosensitizer (PS) has been administered, with electromagnetic radiation containing a wavelength absorbed by said PS at a reduced fluence rate which permits the continued production of singlet oxygen.  
     
     
         3 . The method of  claim 1 , wherein the CNV is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).  
     
     
         4 . The method of  claim 3 , wherein the AMD is the “wet” form.  
     
     
         5 . The method of  claim 1 , wherein the PS is administered as a pharmaceutical composition.  
     
     
         6 . The method of  claim 1 , wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m 2  (PS/body surface area of subject).  
     
     
         7 . The method of  claim 6 , wherein the PS is administered at a concentration of 6 mg/m 2 .  
     
     
         8 . The method of  claim 1 , wherein the PS is administered at a concentration ranging between about 10 μg/kg to 100 mg/kg (PS/body weight of subject).  
     
     
         9 . The method of  claim 1 , wherein the PS is a green porphyrin.  
     
     
         10 . The method of  claim 8 , wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.  
     
     
         11 . The method of  claim 9 , wherein the green porphyrin is BPD-MA.  
     
     
         12 . The method of  claim 8 , wherein the PS is coupled to a specific binding ligand.  
     
     
         13 . The method of  claim 1 , wherein the PS is formulated with a carrier.  
     
     
         14 . The method of  claim 12 , wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.  
     
     
         15 . The method of  claim 1 , wherein the reduced fluence rate is between about 200 mW/cm 2  and about 500 mW/cm 2 .  
     
     
         16 . The method of  claim 14 , wherein the reduced fluence rate is 300 or about 300 mW/cm 2 .  
     
     
         17 . The method of  claim 1 , wherein the electromagnetic radiation contains wavelengths in the visible light spectra.  
     
     
         18 . The method of  claim 1 , wherein the irradiation provides between 12.5 J/cm 2  and 100 J/cm 2 .  
     
     
         19 . The method of  claim 1 , wherein said irradiating occurs between 5 to 30 minutes after administration.  
     
     
         20 . A method of preventing depletion of molecular oxygen in neovasculature during photodynamic therapy (PDT) comprising irradiation with photosensitizer activating radiation at a reduced fluence rate.